deltatrials
Completed NA NCT00057759

Sildenafil in Treating Erectile Dysfunction in Patients With Prostate Cancer

Treatment Of Erectile Dysfunction In Patients Treated On RTOG-9910 For Prostate Cancer: Impact On Patient And Partner Quality Of Life

Sponsor: National Cancer Institute (NCI)

Conditions Prostate Cancer Psychosocial Effects of Cancer and Its Treatment Radiation Toxicity Sexual Dysfunction Sexuality and Reproductive Issues
Interventions Placebo sildenafil citrate
Updated 6 times since 2017 Last updated: Nov 14, 2015 Started: Jan 31, 2003 Primary completion: Dec 31, 2006

This NA trial investigates Prostate Cancer and Psychosocial Effects of Cancer and Its Treatment and is currently completed. National Cancer Institute (NCI) leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  4. Jun 2018 — Jan 2021 [monthly]

    Completed NA

  5. Feb 2017 — Jun 2018 [monthly]

    Completed NA

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed NA

    First recorded

Jan 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • Radiation Therapy Oncology Group
Data source: Radiation Therapy Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States, Ann Arbor, United States, Bryn Mawr, United States, Buffalo, United States, Concord, United States, Hyannis, United States, Inglewood, United States, Kalamazoo, United States, La Crosse, United States, Lebanon, United States and 16 more location s